Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

HIV Infections Clinical Trials

A listing of HIV Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (55) clinical trials

Pharmacokinetic Safety and Efficacy of B/F/TAF in HIV-1 Infected Virologically Suppressed Pregnant Women in Their Second and Third Trimesters

The primary objective of this study is to evaluate the steady state pharmacokinetics of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected, virologically suppressed pregnant women in their second and third trimesters.

Phase

Evaluating the Safety and Pharmacokinetics of VRC01 VRC01LS and VRC07-523LS Potent Anti-HIV Neutralizing Monoclonal Antibodies in HIV-1-Exposed Infants

VRC01, VRC01LS, and VRC07-523LS are anti-HIV neutralizing monoclonal antibodies that may help prevent mother-to-child transmission of HIV. This study will enroll HIV-infected mothers who are at increased risk of passing HIV on to their children. The purpose of this study is to assess the safety and PK of VRC01, VRC01LS, ...

Phase

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVC) Administered Rectally

This study will evaluate the safety and pharmacokinetics of rectal administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels in HIV-uninfected individuals. All participants will receive a single TAF/EVG Insert at Study Visit 3. After a washout period of at least 7 days, participants will receive two ...

Phase

Pembrolizumab in Treating Patients With HIV and Relapsed Refractory or Disseminated Malignant Neoplasms

PRIMARY OBJECTIVES: I. To assess the safety and tolerability of MK-3475 (pembrolizumab) in HIV-infected patients on effective antiretroviral therapy and with relapsed/refractory or disseminated acquired immune deficiency syndrome (AIDS)-defining or non-AIDS defining malignancy. II. To assess the safety and feasibility of MK-3475 (pembrolizumab) administration as first systemic therapy for HIV ...

Phase

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

Objective In this Phase I, proof-of-concept study, we aim to determine the safety and tolerability of pembrolizumab, an FDA-approved monoclonal antibody against programmed cell death protein (PD)-1, in viremically suppressed human immunodeficiency virus-1 (HIV) positive patients. We will also examine the correlation of immune activation and suppression markers in viremically ...

Phase

Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies

This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who ...

Phase

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

Recent advances in antibody cloning technologies have led to the discovery of a number of highly potent and HIV-specific broadly neutralizing monoclonal antibodies (bNAbs) from B cells of HIV-infected individuals. It has been shown that certain bNAbs can prevent acquisition of the virus, suppress viral replication, delay and/or prevent plasma ...

Phase

A Single Dose of Pembrolizumab in HIV-Infected People

A subset of HIV-infected patients, those with poor immunologic response to combined antiretroviral therapy (CD4+ T-cell count of less than 300-350 cells/mm^3) despite control of viremia, are at increased risk for both HIV-related and non-HIV-related complications compared to immunologic responders. Thus, novel approaches for treating HIV infection are needed to ...

Phase

Safety Tolerability Pharmacokinetics and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na ve HIV-1 Infected Participants (MK-8558-002)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8558 monotherapy in anti-retroviral-nave HIV-1 infected participants. The primary hypothesis is that at a dose that exhibits an acceptable safety and tolerability profile, MK-8558 has superior anti-retroviral activity compared to historical placebo data.

Phase

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Phase